1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
J2KBIO Co., Ltd.

J2KBIO Co., Ltd.

KKRX:420570
8,530.00
KRW
+120.00
(+1.43%)
994.28EPS
7.53P/E
43.80BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
228,352.77
224,033.85
229,869.24
3,442.67
5,883.88
5,994.02
5,661.23
7,507.61
Basic EPS, GAAP
38,500.71
23,853.93
26,240.99
448
1,001
-299
459
994.28
Free Cash Flow per Basic Share
-35,380.26
-18,809.28
18,589.83
272.18
350.98
-17.47
162.1
606.2
Dividend per Share
- -
- -
- -
- -
49.64
- -
196.9
- -
Book Value per Share
1,145.58
1,438.23
1,758.63
2,151.47
3,532.89
5,467.4
5,775.41
6,254.08
Tangible Book Value per Share
1,143.93
1,408.57
1,725.43
2,112.64
3,455.19
5,394.64
5,698.28
6,177.4
Basic Weighted Avg Shares
- -
- -
- -
5
5
6
6
6
Sales/Revenue/Turnover
13,772
13,858
14,219
16,032
28,472
33,129
32,966
43,899
Operating Margin (%)
17.51
8.13
13.18
14.5
19.69
10.95
8.86
14.8
Depreciation Expense
63
334
507
557
634
1,118
1,500
918
Net Income, GAAP
2,322
1,475
1,623
2,086
4,844
-1,653
2,673
5,814
Effective Tax Rate (%)
15.54
0.04
- -
5.44
13.89
- -
12.14
16.96
Profit Margin (%)
16.86
10.65
11.42
13.01
17.01
-4.99
8.11
13.24
Working Capital
4,331
4,204
5,745
7,323
10,204
17,287
18,848
17,971
LT Debt
3,719
3,918
3,045
2,253
527
1,848
852
715
Total Equity
5,776
7,251
8,933
10,892
17,811
31,344
33,772
36,571
Return on Invested Capital (%)
- -
10.11
- -
16.47
29.02
- -
7.53
15.17
Return on Capital (%)
- -
14.38
- -
17.21
30.27
- -
7.94
16.5
Return on Common Equity (%)
- -
22.65
20.14
21.17
33.8
-6.72
8.21
16.91

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
283
278
275
LT Borrowings
400
400
400
LT Finance Leases
452
382
315
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
50,288
44,616
43,798

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
21,944
22,505
23,742
Cash, Cash Equivalents & STI
12,701
9,326
9,854
Accounts Receivable, Net
5,401
7,798
8,243
Inventories
3,273
3,832
4,436
Total Current Liabilities
3,095
6,016
5,771
Payables & Accruals
- -
- -
- -
ST Debt
283
278
275
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.48%
7.75%
Free Cash Flow
- -
-267.53%
-1,077.37%
Net Income, GAAP
- -
-45.03%
-261.74%
Sales/Revenue/Turnover
- -
21.76%
-0.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,809
12,043
6,513
6,764
33,129
2025
7,268
8,529
8,563
8,606
32,966
2026
11,126
15,605
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-834
470
-45
50.43
-299
2025
41
151
143.37
122.21
459
2026
272.72
456
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
196.9
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Seop Lee
Full Time Employees
59
Sector
Process industries
Industry
Chemicals: major diversified
Address
Cheongju-si South Korea
Website
j2kbio.com
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
J2KBIO Co., Ltd. is a South Korea-based biotechnology company primarily engaged in the research, development, and commercial manufacturing of bio-active ingredients and functional raw materials for the cosmetics, personal care, and derma-skincare industries. The company utilizes proprietary microorganism strain libraries, bioconversion, and advanced extraction technologies to provide an extensive product portfolio categorized into bio-fermented materials, including skin microbiome-derived active compounds, proprietary Metabiome substances, and fermented plant extracts designed for skin regeneration and anti-aging; natural botanical extracts, encompassing high-purity plant-derived active ingredients for skin brightening, soothing, moisturizing, and barrier enhancement; functional and synthetic active materials, such as targeted anti-inflammatory agents, antioxidant complexes, and UV-damage protection compounds; and customized biotechnology services, comprising custom ingredient synthesis, strain separation, extraction optimization, and OEM/ODM raw material development. J2KBIO serves leading domestic and global cosmetics manufacturers, original design manufacturers (ODMs), and brand conglomerates, including Cosmax, Kolmar Korea, and Cosmecca Korea, with geographic reach spanning South Korea, Asia-Pacific, North America, and Europe. In recent operational developments, J2KBIO completed its public listing on the KOSDAQ market through a business combination with Kyobo 11th Special Purpose Acquisition Company (SPAC) in 2024. Following the listing, the company has expanded its manufacturing capacity and technological capabilities through the establishment of an automated smart manufacturing facility and advanced bio-fermentation research center in Cheongju, launched next-generation skin-microbiome and exosome-based cosmetic active ingredient lines, and broadened international supply partnerships to support the global expansion of indie and prestige skincare brands. Founded in 2017, J2KBIO Co., Ltd. is headquartered in Cheongju-si, Chungcheongbuk-do, South Korea.